We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+0.6%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$112M
AUM Growth
-$4.46M
Cap. Flow
-$3.52M
Cap. Flow %
-3.14%
Top 10 Hldgs %
40.26%
Holding
80
New
27
Increased
7
Reduced
10
Closed
28

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$4.23M
2
CABA icon
Cabaletta Bio
CABA
+$3.68M
3
AUTL
Autolus Therapeutics
AUTL
+$3.62M
4
AMGN icon
Amgen
AMGN
+$3.47M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$3.41M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$4.64M
2
RDY icon
Dr. Reddy's Laboratories
RDY
+$3.56M
3
RNAM
Avidity Biosciences
RNAM
+$3.45M
4
CLDX icon
Celldex Therapeutics
CLDX
+$2.98M
5
GERN icon
Geron
GERN
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMT icon
51
Sagimet Biosciences
SGMT
$451M
$173K 0.15%
50,700
-10,200
-17% -$46.8K
PACB icon
52
Pacific Biosciences
PACB
$460M
$103K 0.09%
75,300
– –
AGIO icon
53
Agios Pharmaceuticals
AGIO
$1.95B
– –
-59,902
Closed -$1.75M
ARWR icon
54
Arrowhead Research
ARWR
$12.3B
– –
-55,700
Closed -$1.59M
JBIO
55
Jade Biosciences
JBIO
$1.22B
– –
-2,814
Closed -$2.91M
BIIB icon
56
Biogen
BIIB
$30.7B
– –
-8,200
Closed -$1.77M
CLDX icon
57
Celldex Therapeutics
CLDX
$3.02B
– –
-71,100
Closed -$2.98M
CYTK icon
58
Cytokinetics
CYTK
$10.9B
– –
-26,008
Closed -$1.82M
ELVN icon
59
Enliven Therapeutics
ELVN
$3.85B
– –
-57,635
Closed -$1.01M
EXAS
60
DELISTED
Exact Sciences
EXAS
– –
-26,700
Closed -$1.84M
GERN icon
61
Geron
GERN
$860M
– –
-886,800
Closed -$2.93M
INZY
62
DELISTED
Inozyme Pharma
INZY
– –
-273,413
Closed -$2.09M
KRYS icon
63
Krystal Biotech
KRYS
$10.8B
– –
-14,700
Closed -$2.62M
OCUL icon
64
Ocular Therapeutix
OCUL
$1.85B
– –
-193,600
Closed -$1.76M
OLMA icon
65
Olema Pharmaceuticals
OLMA
$1.03B
– –
-143,400
Closed -$1.62M
PEN icon
66
Penumbra
PEN
$12.6B
– –
-7,353
Closed -$1.64M
RARE icon
67
Ultragenyx Pharmaceutical
RARE
$2.56B
– –
-17,800
Closed -$831K
RGNX icon
68
Regenxbio
RGNX
$648M
– –
-84,470
Closed -$1.78M
RGLS
69
DELISTED
Regulus Therapeutics
RGLS
– –
-402,504
Closed -$1.16M
RNAM
70
DELISTED
Avidity Biosciences
RNAM
– –
-135,169
Closed -$3.45M
RYTM icon
71
Rhythm Pharmaceuticals
RYTM
$7.25B
– –
-45,603
Closed -$1.98M
TARS icon
72
Tarsus Pharmaceuticals
TARS
$2.6B
– –
-66,300
Closed -$2.41M
TERN
73
DELISTED
Terns Pharmaceuticals
TERN
– –
-227,821
Closed -$1.49M
VTYX
74
DELISTED
Ventyx Biosciences
VTYX
– –
-163,922
Closed -$902K
ITCI
75
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-20,300
Closed -$1.4M
1 2
3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
EWM
Evergreen Wealth Management Williamston, Michigan $194M AUM 13.93% 1-Year Est. Return

Exome Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Exome Asset Management held 80 positions worth $112M, down 3.8% from $117M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Exome Asset Management withdrew a net $3.52M in Q2 2024, closing 28 positions and reducing 10 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $4.64M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Exome Asset Management opened a new position in Sarepta Therapeutics worth $5.2M.

  • Exome Asset Management's largest Q2 2024 buy was Sarepta Therapeutics: 32,900 shares worth $5.2M.
  • Exome Asset Management added most to BridgeBio Pharma in Q2 2024, an estimated $823K increase.
  • Exome Asset Management's biggest Q2 2024 reduction was Dr. Reddy's Laboratories, cutting an estimated $3.56M.
  • Exome Asset Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $4.64M.
  • Exome Asset Management's ten largest holdings make up 40% of its $112M portfolio in Q2 2024.
  • Exome Asset Management opened 27 new positions and closed 28 in Q2 2024.
  • Exome Asset Management's portfolio value fell 3.8% quarter-over-quarter to $112M.

Based on Exome Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.